Health insurance company Humana HUM is set to release its fourth-quarter 2024 earnings report on Feb. 11, before market hours. The stock has dropped 2.37% from the previous close, as of writing, on Feb.10, according to Benzinga Pro. The stock is up 5.58% year-to-date but has fallen 27.73% in the past year.In the previous quarter, Humana reported revenues of $29.4 billion — a 15.2% year-over-year increase. It surpassed analysts’ expectations by 2.6%. The company also achieved a solid beat on earnings per sha ...

Humana Inc. (HUM) is scheduled to release fourth-quarter 2024 results on Feb. 11, before the opening bell. The Zacks Consensus Estimate for earnings is pegged at a loss of $2.26 per share, wider than the prior-year quarter’s loss of 11 cents per share.  See the Zacks Earnings Calendar to stay ahead of market-making news.The fourth-quarter earnings estimate has witnessed one downward revision over the past 30 days. Meanwhile, the Zacks Consensus Estimate for revenues is pegged at $28.8 billion, indicating 12 ...

Analysts on Wall Street project that Humana (HUM) will announce quarterly loss of $2.26 per share in its forthcoming report, representing a decline of 1954.6% year over year. Revenues are projected to reach $28.82 billion, increasing 12% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before ...

New York, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sword Health, an AI health company making world-class, life-changing care accessible anytime, anywhere, today announced the appointment of Bruce Broussard, former CEO of Humana, as a board advisor. Broussard’s extensive experience in healthcare innovation and leadership further strengthens Sword Health’s mission to free the world from pain.  “Bruce’s visionary leadership and unwavering commitment to advancing healthcare accessibility and outcomes make him an inva ...

Humana (HUM) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 11. On ...

Humana (HUM) shares rallied 3.1% in the last trading session to close at $293.80. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.5% gain over the past four weeks.This marks the fourth consecutive day of Humana’s price increases. Increased optimism related to an uptick in Medicare Advantage plan payments for 2026, which would amount to over $21 billion in additional funds for insurers and favorable earning ...

Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorizationThe recently updated American College of Gastroenterology (ACG) Clinical Guideline lists Talicia as a first-line option for treatment of H. pylori infection. Talicia continues to be the most prescribed branded H. pylori therapy by U.S. gastroenterologistsAdditionally, new data describing the foundatio ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Humana (HUM) . This company, which is in the Zacks Medical - HMOs industry, shows potential for another earnings beat.When looking at the last two reports, this health insurer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 18.85%, on average, in the last two quarters.For the ...

Humana Inc. (HUM) benefits from an extensive Medicaid and Medicare membership base, an aging U.S. population, strategic acquisitions and a strong financial position.Humana’s Zacks Rank & Price PerformanceHumana currently carries a Zacks Rank #3 (Hold).The stock has gained 4.9% in the past three months against the industry’s 5.6% decline. The Zacks Medical sector decreased 11.5% while the S&P 500 composite inched up 0.9% in the same time frame.Image Source: Zacks Investment ResearchHUM’s Favorable Style Scor ...

Core Viewpoint - The article emphasizes the importance of value investing and highlights Humana (HUM) as a strong candidate for value investors due to its favorable valuation metrics and earnings outlook [2][3][7] Valuation Metrics - Humana has a Price-to-Book (P/B) ratio of 1.84, which is significantly lower than the industry average of 3.19, indicating that HUM may be undervalued [4] - The Price-to-Sales (P/S) ratio for Humana is 0.3, compared to the industry's average P/S of 0.35, further supporting the notion of undervaluation [5] - Humana's Price-to-Cash Flow (P/CF) ratio stands at 13.65, which is lower than the industry average of 18.50, suggesting a solid cash outlook for the company [6] Investment Outlook - With a Zacks Rank of 2 (Buy) and an A for Value, Humana is positioned as one of the best value stocks currently available [3][7] - The combination of strong valuation metrics and a positive earnings outlook makes Humana an attractive option for value investors at this time [7]